ecotera health develops AI-driven diagnostic platforms to accurately measure microplastics and nanoplastics in human biofluids—including urine, blood, and saliva. Our solutions provide critical insights into environmental exposure, support public health research, large-scale epidemiologic studies and surveillance, enable early detection, and inform personalized interventions.
Translating the Science of Environmental Exposure into
Solutions for Human Health
Human Diagnostics for Microplastics / Nanoplastics
From Environmental Exposure to Clinical Action
Core Technology Platforms
Integrated biomedical platforms bridging environmental exposure science and human health diagnostics.
Advanced Diagnostics
Smartphone-based and laboratory-integrated systems for detection of environmental exposures in biological samples (e.g. urine and blood) for population studies or routine clinical use.
Status: Prototype validated (TRL 4–6)
Precision Therapeutics Developed by Cythera Bio
Multi-mechanism therapeutic candidates targeting exposure-associated diseases including neurodegeneration and cardiovascular conditions.
Therapeutic programs are developed through affiliated platforms, including Cythera Bio.
Status: Drug candidates supported by wet lab data, including ex vivo systems demonstrating measurable changes in particle–biological interactions in the presence of live microbial consortia. Early preclinical development.
AI + Systems Platform
Multi-model AI systems for exposure–biology interaction mapping, diagnostics, candidate discovery, and closed-loop monitoring.
Status: Active development with experimental validation
